RAPT Therapeutics (RAPT) News Today $0.88 +0.04 (+4.79%) (As of 11:24 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Analysts Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) Price Target at $9.50December 13, 2024 | americanbankingnews.comRAPT Therapeutics: Hold Rating Amid Strategic Uncertainties and Financial ResilienceNovember 26, 2024 | markets.businessinsider.comRAPT Therapeutics Reprices Underwater Employee Stock OptionsNovember 16, 2024 | markets.businessinsider.comFY2024 Earnings Estimate for RAPT Issued By Leerink PartnrsRAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Equities researchers at Leerink Partnrs boosted their FY2024 EPS estimates for shares of RAPT Therapeutics in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($2.3November 15, 2024 | marketbeat.comRAPT Therapeutics Reports Improved Q3 2024 ResultsNovember 14, 2024 | markets.businessinsider.comWhat is Leerink Partnrs' Estimate for RAPT FY2024 Earnings?RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of RAPT Therapeutics in a research report issued to clients and investors on Monday, November 11th. Leerink Partnrs analyst T. Smith now expects thaNovember 14, 2024 | marketbeat.comRAPT Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comRAPT Therapeutics: Strategic Shift to Next-Gen Compounds Boosts Buy Rating Despite Program TerminationNovember 13, 2024 | markets.businessinsider.comRAPT Therapeutics (NASDAQ:RAPT) Receives "Hold" Rating from Stifel NicolausStifel Nicolaus reiterated a "hold" rating and issued a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday.November 13, 2024 | marketbeat.comWells Fargo & Company Issues Pessimistic Forecast for RAPT Therapeutics (NASDAQ:RAPT) Stock PriceWells Fargo & Company decreased their price target on RAPT Therapeutics from $17.00 to $4.00 and set an "overweight" rating on the stock in a research note on Tuesday.November 12, 2024 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Receives "Neutral" Rating from HC WainwrightHC Wainwright reissued a "neutral" rating on shares of RAPT Therapeutics in a research report on Tuesday.November 12, 2024 | marketbeat.comBased on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver InjuryNovember 12, 2024 | markets.businessinsider.comJP Morgan Downgrades RAPT Therapeutics (RAPT)November 12, 2024 | msn.comRAPT scraps zelnecirnon program, stock plunges 46% (update)November 11, 2024 | seekingalpha.comRapt Therapeutics Stops Development of Asthma, Atopic Dermatitis Drug Candidate After Reaction Sidelines TrialsNovember 11, 2024 | marketwatch.comRAPT Shares Fall to All-Time Low After Zelnecirnon Programs TerminatedNovember 11, 2024 | marketwatch.comRAPT scraps zelnecirnon program, stock plunges 44%November 11, 2024 | msn.comJPMorgan cuts Rapt Therapeutics to Underweight after zelnecirnon discontinuedNovember 11, 2024 | markets.businessinsider.comRapt Therapeutics model under review at Stifel after zelnecirnon discontinuedNovember 11, 2024 | markets.businessinsider.comRAPT Therapeutics shares tumble by 48% after zelnecirnon programme cullNovember 11, 2024 | finance.yahoo.comRAPT Therapeutics (NASDAQ:RAPT) Lowered to "Underweight" Rating by JPMorgan Chase & Co.JPMorgan Chase & Co. cut shares of RAPT Therapeutics from a "neutral" rating to an "underweight" rating in a report on Monday.November 11, 2024 | marketbeat.comRapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver InjuryNovember 11, 2024 | benzinga.comCompanies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite RiskyNovember 9, 2024 | finance.yahoo.comPromising Risk-Reward Scenario for RAPT Therapeutics: A Buy Rating Amid Clinical Uncertainties and Valuation ConsiderationsNovember 6, 2024 | markets.businessinsider.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of "Hold" by BrokeragesRAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten analysts that are currently covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold recommendation and one has givenOctober 21, 2024 | marketbeat.comPoint72 Asset Management L.P. Buys 706,900 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)Point72 Asset Management L.P. increased its stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 176,725.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 707,300 shares of the company's stock after purcOctober 4, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Bought by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC grew its position in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 826.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 295,241 shares of the company's stockOctober 3, 2024 | marketbeat.comRAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy NowSeptember 29, 2024 | finance.yahoo.comGastric Cancer Pipeline Insights, Treatment Drugs, Clinical Trials and Companies 2024September 27, 2024 | theglobeandmail.comRAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite UnprofitabilitySeptember 25, 2024 | msn.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Bought by Federated Hermes Inc.Federated Hermes Inc. grew its holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 188.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 796,080 shares of the company's stock after buSeptember 20, 2024 | marketbeat.comAcadian Asset Management LLC Raises Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)Acadian Asset Management LLC raised its holdings in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 4,183.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 467,182 shares of the company's stock after acqSeptember 16, 2024 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) PT Lowered to $2.00UBS Group cut their price target on RAPT Therapeutics from $10.00 to $2.00 and set a "neutral" rating on the stock in a research report on Monday.September 9, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of "Hold" from AnalystsShares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) have been assigned a consensus recommendation of "Hold" from the eleven ratings firms that are currently covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold recommendatioSeptember 1, 2024 | marketbeat.comRAPT Therapeutics, Inc. (RAPT) Stock Price, News, Quote & History - Yahoo FinanceAugust 30, 2024 | finance.yahoo.comHC Wainwright Comments on RAPT Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:RAPT)RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Equities researchers at HC Wainwright boosted their Q3 2024 earnings estimates for shares of RAPT Therapeutics in a note issued to investors on Tuesday, August 20th. HC Wainwright analyst R. Selvaraju now expects that the company will post earAugust 22, 2024 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), RAPT Therapeutics (RAPT) and Liquidia Technologies (LQDA)August 20, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Neutral Rating for RAPT Therapeutics (NASDAQ:RAPT)HC Wainwright reiterated a "neutral" rating on shares of RAPT Therapeutics in a research note on Tuesday.August 20, 2024 | marketbeat.comPrelude Therapeutics Inc Q2 Loss Misses EstimatesAugust 12, 2024 | markets.businessinsider.comVanguard Group Inc. Raises Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)Vanguard Group Inc. lifted its holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 21.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,492,850 shares of the company's stock after buying an additional 436,629 sharesAugust 11, 2024 | marketbeat.comRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024August 9, 2024 | markets.businessinsider.comRAPT Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | finance.yahoo.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by BrokeragesRAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been given a consensus recommendation of "Hold" by the thirteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a hold recommendation and four have assigned a buy reAugust 7, 2024 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 1,385,386 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)Price T Rowe Associates Inc. MD reduced its holdings in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 40.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,028,August 3, 2024 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of RAPT Therapeutics in a research report on Tuesday.July 23, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of "Hold" from AnalystsShares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) have been given a consensus rating of "Hold" by the thirteen analysts that are covering the stock, Marketbeat reports. Nine analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the comJune 18, 2024 | marketbeat.comOctagon Capital Advisors LP Takes $7.26 Million Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)Octagon Capital Advisors LP bought a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 292,000 shares of the company's stockJune 15, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Stake Reduced by Great Point Partners LLCGreat Point Partners LLC lowered its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 24.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,099,753 shares of the company'sJune 13, 2024 | marketbeat.comBraidwell LP Reduces Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)Braidwell LP lessened its holdings in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 64.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 389,300 shares of the company's stock after selling 693,212 sharJune 12, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of "Hold" by AnalystsRAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been assigned a consensus rating of "Hold" from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation and four have issued a buy recMay 24, 2024 | marketbeat.com Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Uncover the Top Gold Stock of the Bull Market (Ad)Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play? Click here to see how this opportunity could transform your portfolio. RAPT Media Mentions By Week RAPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAPT News Sentiment▼0.500.59▲Average Medical News Sentiment RAPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAPT Articles This Week▼22▲RAPT Articles Average Week Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aligos Therapeutics News Today Editas Medicine News Today Inventiva News Today Acumen Pharmaceuticals News Today Leap Therapeutics News Today Metagenomi News Today Protara Therapeutics News Today X4 Pharmaceuticals News Today INmune Bio News Today Adverum Biotechnologies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RAPT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RAPT Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
